The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.
 
Mustafa Özgüroğlu
Honoraria - Astellas Pharma; Janssen Oncology (Inst); Novartis
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jonathan W. Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Yuanbin Chen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Guardant Health; Jazz Pharmaceuticals; Merck; Pfizer; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Merck Serono (Inst)
Expert Testimony - AstraZeneca; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Ipsen
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Nenad Medic
Employment - AstraZeneca/MedImmune; PAREXEL
 
Helen Mann
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Priti Chugh
Employment - AstraZeneca/MedImmune
 
Tapashi Dalvi
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Hutchmed (I); Ipsen; Lilly; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)